Milestone payments eligible to receive.

No definition available.

Name:	tptx_MilestonePaymentsEligibleToReceive
Namespace Prefix:	tptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tptx_ZaiRepotrectinibAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=tptx_ClinicalSupplyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=tptx_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=tptx_ZaiElzovantinibAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Zai License Agreements - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jan. 10, 2021	Jul. 31, 2020
License
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized				$ 25,000,000.0
Zai Repotrectinib Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment received						$ 25,000,000.0
Total transaction price allocated to performance obligation	$ 25,700,000
Zai Repotrectinib Agreement \| Clinical Supply
Research And Development Arrangement Contract To Perform For Others [Line Items]
Total transaction price allocated to performance obligation	700,000
Revenue recognized	400,000		$ 200,000
Zai Repotrectinib Agreement \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive						151,000,000.0
Zai Repotrectinib Agreement \| Development Milestones [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 5,000,000.0
Zai Repotrectinib Agreement \| Development Milestones [Member] \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive						46,000,000.0
Zai Repotrectinib Agreement \| Sales Milestones \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive						$ 105,000,000.0
Zai Elzovantinib Agreement [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront cash payment received			25,000,000.0
Total transaction price allocated to performance obligation	25,900,000
Zai Elzovantinib Agreement [Member] \| License
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized			$ 25,000,000.0
Zai Elzovantinib Agreement [Member] \| Clinical Supply
Research And Development Arrangement Contract To Perform For Others [Line Items]
Total transaction price allocated to performance obligation	900,000
Revenue recognized	$ 0
Zai Elzovantinib Agreement [Member] \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive					$ 336,000,000.0
Zai Elzovantinib Agreement [Member] \| Development Milestones [Member] \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive					121,000,000.0
Zai Elzovantinib Agreement [Member] \| Sales Milestones \| Maximum [Member]
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments eligible to receive					$ 215,000,000.0